This literature review article discusses the latest developments in the mechanism and role of dipeptidyl peptidase 4 (DPP4) actions in the severity of diseases, particularly in women with polycystic ovary syndrome PCOS, coronavirus disease 2019, autoimmune thyroid diseases, diabetic patients, cardiovascular disease, cancer, and clarified the functions of DPP4 inhibitors in variety of diseases. Recent scientists have revealed experimental, preclinical, and clinical data for DPP4 inhibitors, which demonstrate the enzyme's functional role in illness treatment or severity reduction. Interestingly, DPP4 actions are a complicated mechanism, with numbers of metabolic pathways engaged depending on the kind and severity of the disease. DPP4 is one of the serine proteolytic enzymes that function via multiple biochemical processes mediators in a variety of endocrinological tissues, including the effect on the regulation of the incretin hormones, play a major role in regulate insulin secretion based on blood glucose. Interestingly, current experimental and preclinical findings suggest that DPP4 inhibitors may also maintain glycemic control in PCOS disease development, have beneficial effects in cancer, and prevent cardiovascular disease in T2DM. In this present review, we summarized the impacts of DPP4 inhibitors therapies based on the latest studies, as well as the possible mechanism of action and the effects of DPP4 enzyme levels and activity with its relation to disease progression.
Albaidhani et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: